Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Background: Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to investigate the efficacy and safety of 12 months of neratinib after trastuzumab-based adjuvant therapy in patients with...

Full description

Bibliographic Details
Main Authors: Chan, Arlene, Delaloge, S., Holmes, F., Moy, B., Iwata, H., Harvey, V., Robert, N., Silovski, T., Gokmen, E., von Minckwitz, G., Ejlertsen, B., Chia, S., Mansi, J., Barrios, C., Gnant, M., Buyse, M., Gore, I., Smith, J., Harker, G., Masuda, N., Petrakova, K., Zotano, A., Iannotti, N., Rodriguez, G., Tassone, P., Wong, A., Bryce, R., Ye, Y., Yao, B., Martin, M.
Format: Journal Article
Published: Elsevier 2016
Online Access:http://hdl.handle.net/20.500.11937/31355

Internet

http://hdl.handle.net/20.500.11937/31355

Similar Items